Compare · ILMNV vs WAT
ILMNV vs WAT
Side-by-side comparison of Illumina Inc. (ILMNV) and Waters Corporation (WAT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ILMNV and WAT operate in Biotechnology: Laboratory Analytical Instruments (Health Care), so they compete in similar markets.
- WAT carries a market cap of $45.81B.
- WAT has hit the wire 9 times in the past 4 weeks while ILMNV has been quiet.
- WAT has more recent analyst coverage (25 ratings vs 0 for ILMNV).
- Company
- Illumina Inc.
- Waters Corporation
- Price
- -
- -
- Market cap
- -
- $45.81B
- 1M return
- -
- +5.25%
- 1Y return
- -
- +23.83%
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 1995
- News (4w)
- 0
- 9
- Recent ratings
- 0
- 25
Waters Corporation
Waters Corporation, a specialty measurement company, provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments, Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans. It also designs, manufactures, sells, and services thermal analysis, rheometry, and calorimetry instruments; and develops and supplies software-based products that interface with its instruments, as well as other manufacturers' instruments. Its MS technology instruments are used in drug discovery and development comprising clinical trial testing, the analysis of proteins in disease processes, nutritional safety analysis, and environmental testing. The company's offers thermal analysis, rheometry, and calorimetry instruments for use in predicting the suitability and stability of fine chemicals, pharmaceuticals, water, polymers, metals, and viscous liquids for various industrial, consumer good, and healthcare products, as well as for life science research. Its products are used by pharmaceutical, biochemical, industrial, nutritional safety, environmental, academic, and governmental customers working in research and development, quality assurance, and other laboratory applications. The company has a collaboration with Genovis AB to develop and market biopharmaceutical characterization workflows based on the its BioAccord LC-MS System, Andrew+ pipetting robot and Genovis SmartEnzymes. Waters Corporation was founded in 1958 and is headquartered in Milford, Massachusetts.
Latest ILMNV
- SVP, Chief Commercial Officer Cunningham Everett was granted 36,860 shares (SEC Form 4)
- Director Ullem Scott B. was granted 205 shares, increasing direct ownership by 5% to 4,550 units (SEC Form 4)
- Amendment: Illumina Inc. filed SEC Form 8-K: Costs Associated with Exit or Disposal Activities
- Amendment: Illumina Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits
Latest WAT
- Waters Corporation to Present at the 9th Annual Evercore Healthcare Conference
- SVP Waters Analytical Sciences Wu Tong (Nmn) was granted 1,081 shares (SEC Form 4)
- SEC Form 10-Q filed by Waters Corporation
- Waters Achieves FDA 510(k) Clearance for Ready-to-Use Flow Cytometry Clinical Tests for Leukemia and Lymphoma
- New insider Conly D Steven claimed ownership of 6,030 shares (SEC Form 3)
- Waters Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Waters Corporation (NYSE: WAT) Reports Third Quarter 2026 Financial Results
- Waters Acquires MOBILion Systems, Bringing Advanced Ion-Mobility Separation to its Mass Spectrometry Portfolio with the Speed and Resolution AI Workflows Require for Proteomics Biomarker Discovery
- Waters Launches AI-Powered Peak Integration Expanding its Suite of Premium AI Subscription Capabilities for Empower Software
- Waters and Labcorp to Expand Access to Cervical Cancer Screening with the Most Comprehensive FDA-Approved HPV Testing Option Beginning in Late 2026